Category Archives: New York Stem Cells

New York, July 29, 2022 (GLOBE NEWSWIRE) -- According to the statistics by the Organ Procurement Transplantation Network (OPTN), by the United States Department of Health & Human Services, during the period January and June 2022, a total of 20663 transplants were performed in the United States, whereas 10286 donors were recovered during the same period. Further, as of 19th of July 2022, a total of 105980 candidates are in the waiting list to perform different types of transplants. On the other hand, according to the statistics by the European Society of Blood and Marrow Transplantation (EBMT), in the year 2019, the total number of HCT performed in Europe was 48512, which included 43581 first time HCT and 4931 re/additional transplants.

Research Nester examined the statistical and analytical approach that is required for the growth of Global Hematopoietic Stem Cell Transplant (HPSCT) Market' between the years 2021 and 2029. The key industrial insights provided in the report gives a better idea about the market overview to the readers regarding the existing scenario in the market. The report further includes in-depth market analysis in five major regions, i.e., North America, Latin America, Europe, Asia Pacific and Middle East & Africa, including the current and future industry trends, innovations, and challenges, along with strategies that will help industry players to attain their business targets.

Get a sample copy of the report@ https://www.researchnester.com/sample-request-2889

A research conducted by Worldwide Network for Blood and Marrow Transplantation (WBMT) estimated that in 2019, nearly 1.5 million HSCTs were performed globally. Over the last two decades, hematopoietic stem cell transplant (HSCT) has seen rapid expansion to become the standard of care for many patients with congenital or acquired disorders of the hematopoietic system or with chemo- radio- or, immuno- sensitive malignancies, such as lymphoma, leukemia, solid tumors, and others. Diseases, such as blood cancer (leukemia, and lymphoma), auto-immune diseases, immunodeficiency, and genetic disorders are growing in number around the world. In 2020, according to a report by the International Agency of Research on Cancer (IARC), on a global scale, out of every 100,000 individuals, 336,669 individuals were suffering from leukemia, 64,067 with Hodgkin lymphoma, and 399,610 with non-Hodgkin lymphoma. Hematopoietic stem cells have the potency to produce more blood cells, i.e., red blood cells, white blood cells, and platelets. Based on these factors, the global hematopoietic stem cells transplantation market is estimated to grow at a substantial CAGR over the forecast period, i.e., 2021-2029.

Moreover, growing adoption of stem cell transplants across the medical industry is also expected to drive the market growth. For instance, as of 2017, over 20,000 stem cell transplants, annually, were performed for hematologic malignancies in the United States, out of which, approximately 60% were allogeneic and 40% were autologous. Furthermore, the growing awareness amongst people regarding early diagnosis of rare diseases, along with the adoption of advanced treatment methods, and growing healthcare expenditure are also expected to drive the market growth.

For more information in the analysis of this report, visit: https://www.researchnester.com/reports/hematopoietic-stem-cell-transplant-market/2889

Geographically, the global hematopoietic stem cell transplant (HPSCT) market is segmented by region into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. Amongst the market in these regions, the market in North America held the leading market share in the year 2021 and is further projected to garner the largest market share during the forecast period. High prevalence of leukemia and lymphoma in the region is one of the major factors anticipated to drive the growth of the market. In the United States, about 60,650 cases of leukemia were reported in 2021, as per data by the American Cancer Society, out of which, 20,050 cases were of acute myeloid leukemia (AML). Further, in 2018, a total of 22,729 hematopoietic cell transplants (HCTs) were performed in the United States, as reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). This number grew to 23,073 in 2019.

Further, the market in Asia Pacific region is estimated to witness noteworthy growth over the forecast period on the back of growing incidences of blood cancer, along with rising health awareness amongst the people. According to GLOBOCAN 2020' report by the IARC, a number of 2,41,270 non-Hodgkin lymphoma and 31,742 Hodgkin lymphoma were reported in Asia. Moreover, the increasing disposable income in the region is also estimated to propel the market growth.

Get a Sample PDF of Hematopoietic Stem Cell Transplant Market Report@ https://www.researchnester.com/sample-request-2889

The study further incorporates Y-O-Y growth, demand & supply and forecast future opportunity in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa).

The global hematopoietic stem cell transplant (HSCT) market is segmented by disease indication into lymphoproliferative disorders, leukemia, and non-malignant disorders. The leukemia segment is further divided into acute myeloid leukemia (AML), acute lymphatic leukemia (ALL), myelodysplastic syndrome (MDS), and others. Amongst these segments, the acute myeloid leukemia (AML) segment is projected to display a moderate revenue during the forecast period, backed by the rising prevalence of the disease type. For instance, it has been observed that AML makes up to about 30% of all leukemia cases amongst adults and that the average age of diagnosis of the disease is at around 68.

For more insights on the market share of various regions: https://www.researchnester.com/sample-request-2889

The global hematopoietic stem cell transplant (HSCT) market is also segmented on the basis of transplant type into allogeneic and autologous. Amongst these segments, the allogeneic transplant segment generated the largest market share in the year 2021 and is further projected to attain a significant market revenue during the forecast period. The major factor anticipated to drive the growth of the segment is the numerous benefits associated with the process, which include the formation of a new immune system in patients undergoing this transplant type after the donated cells are engrafted into the body of the patient. Further, the autologous segment is projected to grow with a significant CAGR during the forecast period, backed by the rising availability of donors for this type of transplantation process and for the surge in the number of transplantation process by using this type. For instance, in the other statistics by the EBMT, the total number of allogeneic and autologous transplants performed in the year 2019 in Europe reached 19798 and 28714 respectively.

The global hematopoietic stem cell transplant (HSCT) market is segmented on the basis of application.

Global Hematopoietic Stem Cell Transplant (HSCT) Market, Segmentation by Application

Do You Have Any Query Or Specific Requirement? Ask to Our Expert: https://www.researchnester.com/ask-the-analyst/rep-id-2889

Some of the prominent players and their company profiling included in the report are Lonza Group Ltd., Escape Therapeutics, Inc., Regen BioPharma, Inc., ThermoGenesis Holdings, Inc., CSG-BIO Company, Inc. (CellSave), CBR Systems, Inc., Pluristem Inc., Global Cord Blood Corporation, ViaCord, LLC, Cynata Therapeutics Limited, and others. The profiling enfolds growth opportunities, challenges, market trends, competitive analysis and positioning, along with the strategies used by them to stay ahead of their competitors.

Explore Our Recent Related Reports:

Catheter Securement & Stabilization Device Market Segmentation By Product (Central Venous Catheter Securement, Arterial Catheter Securement, Peripheral Catheter Securement, Urinary Catheter Securement and Others); By End User (Hospitals, Ambulatory Surgical Centers, Clinics, Home Care and Others) Global Demand Analysis & Opportunity Outlook 2027Elastomeric Infusion Pumps Market Segmentation By Product (Continuous Rate Elastomeric Pumps and Variable Rate Elastomeric Pumps); By Application (Pain Management, Infection Management, Chemotherapy and Others); By Route of Administration (Intravenous, Intra-Arterial, Subcutaneous, Epidural and Intramuscular); By End User (Hospitals, Ambulatory Surgical Centers, Clinics, Home Care and Others) Global Demand Analysis & Opportunity Outlook 2027Dialysis Device Market Segmentation By Product (Hemodialysis Devices And Peritoneal Dialysis Devices); By End User (Hospitals, Dialysis Centers, Home Care And Others) Global Demand Analysis & Opportunity Outlook 2027Renal Disease Treatment Market Segmentation By Disease (Acute Kidney Failure, Chronic Kidney Disease [CKD], End-Stage Renal Disease [ESRD] and Others); By Treatment (Drugs, Surgery, Dialysis, Kidney Transplant and Others); By End User (Hospitals, Clinics, Dialysis Centers, Home Care and Others) Global Demand Analysis & Opportunity Outlook 2027Transfusion Disposable Products Market Segmentation By Product (Infusion Bags, Disposable Syringe and PVC Tubes); By End User (Hospitals, Ambulatory Surgical Centers, Clinics, Blood Banks and Others) Global Demand Analysis & Opportunity Outlook 2027

About Research Nester

Research Nester is a one-stop service provider with a client base in more than 50 countries, leading in strategic market research and consulting with an unbiased and unparalleled approach towards helping global industrial players, conglomerates and executives for their future investment while avoiding forthcoming uncertainties. With an out-of-the-box mindset to produce statistical and analytical market research reports, we provide strategic consulting so that our clients can make wise business decisions with clarity while strategizing and planning for their forthcoming needs and succeed in achieving their future endeavors. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds.

Contact for more Info:AJ DanielEmail:info@researchnester.comU.S. Phone: +1 646 586 9123U.K. Phone: +44 203 608 5919

For More Update Follow: -LinkedIn|Twitter|Facebook|Xing

Go here to read the rest:
Global Hematopoietic Stem Cell Transplant (HSCT) Market to be Driven by Increasing Prevalence of Blood Ca - Benzinga

An image came to Chelsea G. Summers: a boyfriend, accidentally on purpose hit by a car, some quick work with a corkscrew and his liver served Tuscan style, on toast.

That figment of her twisted imagination is what prompted Ms. Summers to write her novel, A Certain Hunger, about a restaurant critic with a taste for (male) human flesh.

Turns out, cannibalism has a time and a place. In the pages of some recent stomach-churning books, and on television and film screens, Ms. Summers and others suggest that that time is now.

There is Yellowjackets, a Showtime series about a high school womens soccer team stranded in the woods for a few months too many, which premiered in November. The film Fresh, released on Hulu in March, involves an underground human meat trade for the rich.

Lapvona, Ottessa Moshfeghs novel published in June, portrays cannibalism in a medieval village overcome by plague and drought. Agustina Bazterricas book Tender Is the Flesh, released in English in 2020 and in Spanish in 2017, imagines a future society that farms humans like cattle. Also out in 2017, Raw, a film by the director and screenwriter Julia Ducournau, tells the story of a vegetarian veterinary student whose taste for meat escalates after consuming raw offal.

Still to come is Bones and All, starring Timothe Chalamet. The movie, about a young love that becomes a lust for human consumption, is expected to be released later this year or early next. Its director, Luca Guadagnino, has called the story extremely romantic.

A fascination with cannibalism, perhaps not surprisingly, can toe a fine line, as Ms. Summers learned while writing A Certain Hunger.

When fact checkers came calling about the frenzied scenes in which the books antiheroine prepares her murdered lovers with grotesque, epicurean flourish, their queries about the intricacies of human butchery left Ms. Summers so disturbed that she went full raw vegan for two weeks. The creator was horrified by her own monster.

Publishers may have been, too. When Ms. Summers, who uses a pseudonym, was shopping the book around in 2018, it was rejected more than 20 times before Audible and the Unnamed Press made an offer.

If she were selling A Certain Hunger today, Ms. Summers, who is 59 and lives in New York and Stockholm, believes it would be easier. God bless Yellowjackets, she said in a Zoom interview, which was later interrupted by her dog, Bob, vomiting in the background.

Released in December 2020, her book started to experience a boom in popularity on social media the actress Anya Taylor-Joy posted about it on Instagram, and it received many plaudits in the corner of TikTok known as BookTok about a year later, around the time that Yellowjackets debuted on Showtime.

The pilot episode of Yellowjackets shows a teenage girl getting trapped, bled out like a deer and served on a platter in a terrifying ritual. Bloodthirsty fans continue to dissect the scene on Reddit, where a subreddit message board dedicated to the series has more than 51,000 members.

The shows tension is in the knowledge that you know cannibalism is coming, but when? And why?

The creators of Yellowjackets, Ashley Lyle and Bart Nickerson, who live in Los Angeles, say they wanted the plot to hint that human consumption wasnt merely for the characters survival. This not only adds a spine-tingling creepiness to the already dark story about the soccer team stranded in the wilderness, but also separates it from the real-life tale of a Uruguayan rugby team trapped in the Andes in 1972, whose members resorted to cannibalism to survive. (That event was later dramatized in a 1993 movie, Alive, starring Ethan Hawke.)

I think were often drawn to the things that repulse us the most, Ms. Lyle, 42, said. Mr. Nickerson, 43, chimed in: But I keep coming back to this idea of, what portion of our revulsion to these things is a fear of the ecstasy of them?

Lapvona, by Ms. Moshfegh, is also not overtly cannibalistic; unlike A Certain Hunger, theres no braising with bouquet garni. But one scene involving a toenail is harrowing.

Known for her unsettling, delving-into-the-darkness stories including Eileen and My Year of Rest and Relaxation, Ms. Moshfegh, 41, who lives in Los Angeles, wrote Lapvona during the spring of 2020, in the early days of the pandemic. I wrote it in such complete isolation that I felt this incredible freedom to go wherever I was being led, she said.

The character who eats another human, the greatest sin in his religiously vegetarian village, does so in an act of depraved desperation, said Ms. Moshfegh, a vegetarian herself.

Bill Schutt, the author of Cannibalism: A Perfectly Natural History, says that fictional plots about eating human flesh are as old as literature itself.

When you take something that is so horrible and put it through this lens of fictionalization, he said, we get charged up about it, but we know were safe. At least most of the time: Dr. Schutt only made it halfway through Hulus Fresh before he had to stop the movie. It was almost too well done, he said.

But as his book documents, cannibalism has occurred around the world throughout history, lending these fictional tales a queasy whiff of what if?

Historical examples in the book include mumia, a practice of using ground-up mummified bones to soothe various ailments that was popular in 17th-century Western Europe; the infamous Donner Party pioneers who became trapped in the Sierra Nevada in 1846; ritual cannibalism that took place in Papua New Guinea until the 1950s; and famine-induced cannibalism in China in the 1960s.

Dr. Schutts book also features the story of the so-called Cannibal Cop, a former New York Police Department officer who was arrested in 2013 for participating in fetish forums that fantasized about cannibalizing women, and later acquitted. The New York Post has published more than 30 articles about the case, including one suggesting the Halloween costume of a policemans uniform with a severed hand on a plate.

Flavors of that saga can be found in the more recent accusations of sexual and physical abuse against the actor Armie Hammer, which have included that he allegedly sent cannibalistic messages to a romantic partner. Mr. Hammer has denied the accusations and, through his lawyer, declined to comment for this article.

After the allegations became public, he was dropped by his agency, checked into rehab and is now, Variety reports, selling time shares in the Cayman Islands. Coincidentally, Mr. Hammer worked with Mr. Chalamet and Mr. Guadagnino on Call Me by Your Name.

As to what may be fueling the desire for cannibalism stories today, Ms. Lyle, the Yellowjackets co-creator, said, I think that were obviously in a very strange moment. She listed the pandemic, climate change, school shootings and years of political cacophony as possible factors.

I feel like the unthinkable has become the thinkable, Ms. Lyle said, and cannibalism is very much squarely in that category of the unthinkable.

According to Ms. Summers, cannibalism is always symbolic. For her novels protagonist, eating human flesh can be seen as a way of holding on to a relationship that ended. For Ms. Summers herself, the plot of A Certain Hunger cant be uncoupled from my own personal experiences with disordered eating, with the tamping down of feminine appetites, the way the media chews up and spits out writers, bougie consumption and bougie lady consumption, she said.

More generally, Ms. Summers thinks that the recent spate of cannibalistic plots could also be commentaries on capitalism. Cannibalism is about consumption and its about burning up from the inside in order to exist, she said. Burnout is essentially over-consuming yourself, your own energy, your own will to survive, your sleep schedule, your eating schedule, your body.

Ms. Moshfegh said her theory was that it might be an antidote to the actual horror of whats happening to the planet. Like Ms. Summers, Ms. Moshfegh at times couldnt stomach her own work, describing the process of writing about cannibalism in Lapvona as a bit disturbing.

I had to think about what part of the body would be an interesting place to start, she said, and how it would feel to hold someones severed hand in yours.

The prop team on Yellowjackets had a similarly unnerving task in determining what to use as faux human flesh in the shows pilot episode.

Should it be the lab-grown human steak made from stem cells that spurred outrage at a London museum? The animal-free chicken, beef, salmon and dairy substitutes that some companies are creating using similar technology?

Ultimately, the prop team went with venison.

But theyll have to find an alternative for future episodes, Ms. Lyle and Mr. Nickerson said, because many in its cast are vegan.

Original post:
Why Are There so Many Books and Shows About Cannibalism? - The New York Times

Market Overview

Thecell culture media marketis expected to cross USD 4.33 billion by 2027 at a CAGR of8.33%.

Market Dynamics

The markets growth is being fueled by a diverse range of cell culture media applications, increased research and development in the pharmaceutical industry, an increase in the prevalence of chronic diseases, and increased expansion and product launches by major players. Over the last few decades, advancements in cell culture technology have accelerated. It is widely regarded as one of the most dependable, robust, and mature technologies for biotherapeutic product development.

The high cost of cell culture media and the risk of contamination, on the other hand, are impeding the markets growth. However, the growing emphasis on regenerative and personalized medicine is likely to spur growth in the global cell culture media market.

Get Sample Report: https://www.marketresearchfuture.com/sample_request/4462

Competitive Dynamics

The notable players are the Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), GE Healthcare (US), Becton, Dickinson and Company (US), HiMedia Laboratories (India), Corning Incorporated (US), PromoCell (Germany), Sera Scandia A/S (Denmark), The Sartorius Group (Germany), and Fujifilm Holdings Corporation (Japan).

Segmental Analysis

The global market for cell culture media has been segmented according to product type, application, and end user.

The market has been segmented by product type into classical media, stem cell media, serum-free media, and others.

Further subcategories of stem cell culture media include bone marrow, embryonic stem cells, mesenchymal stem cells, and neural stem cells.

The market is segmented into four application segments: drug discovery and development, cancer research, genetic engineering, and tissue engineering and biochemistry.

The market is segmented by end user into biochemistry and pharmaceutical companies, research laboratories, academic institutions, and pathology laboratories.

Regional Overview

According to region, the global cell culture media market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas dominated the global cell culture media market. The large share is attributed to the presence of major manufacturers, rising disease prevalence resulting in increased demand for drugs and other medications, technological advancements in the preclinical and clinical segments, growing public awareness, and high disposable income.

Europe ranks second in terms of market size for cell culture media. Factors such as an increase in the biopharmaceutical sector in the European region, increased government initiatives to promote research to find a cure for the growing number of chronic diseases, an increase in the number of pharmaceutical manufacturers, improving economies, a high disposable income per individual, and increased healthcare spending are all contributing to the markets growth in this region. The European market is expected to be driven by expanding R&D activities and a developing biopharmaceutical sector.

Asia-Pacific held the third-largest market share, owing to the presence of numerous research organizations, low manufacturing costs, low labor costs, developing healthcare infrastructure, and increased investment by American and European market giants in Asian countries such as China and India.

The Middle East and Africa, with limited economic development and extremely low income, held the smallest market share in 2019 but is expected to grow due to growing public awareness and demand for improved healthcare facilities in countries, as well as rising disposable income.

Browse Full Reports: https://www.marketresearchfuture.com/reports/cell-culture-media-market-4462

Related Report: Dysmenorrhea Treatment Market Research Report- Global Forecast to 2027

Syringe and Needle Market Research Report Global Forecast to 2027

Global Medical Robotics Market Research Report- Forecast To 2027

About US:

Market Research Future (MRFR) enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

Here is the original post:
Cell Culture Media Market: Competitive Approach, Breakdown And Forecast by 2027 - Digital Journal

Our new studies demonstrate something for the first time and its the holy grail of wellness: We can actually reverse the biology of aging and take cellular and brain function back in time.

MIAMI (PRWEB) July 26, 2022

The Global Wellness Summit (GWS), the most prestigious conference on the $4.4 trillion business of wellness, announced today that Shai Efrati, MD, the worlds foremost research scientist on hyperbaric oxygen therapy, will keynote at the conference being held at the Hilton Tel Aviv from October 31 to November 3. Efrati is a professor at Sackler School of Medicine and the Sagol School of Neuroscience at Tel Aviv University and director of the Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Centerthe largest hyperbaric center in the world, treating over 350 patients a day.

Efratis lab has created a unique approach for hyperbaric oxygen therapy (HBOT) which consists of immersing people in a high-pressure, high-oxygen environment and then carefully regulating oxygen and pressure levels. This technique, which is called the hyperoxic-hypoxic paradox (HHP), tricks the body into entering a regenerative state which unleashes a cascade of biological changes. These include the proliferation of stem cells, the generation of new blood vessels, and the repair of brain cells and tissue.

Eye-opening evidence:

Over the last decade, Efratis research team has authored dozens of high-quality clinical studies that show how this specific HBOT therapy revolving around the hyperoxic-hypoxic paradox has eye-opening impact on so many conditions. It can significantly boost brain function in stroke and traumatic brain injury patients, heal the wounds in the brain caused by PTSD, improve sexual function, and roll back the process of skin aging. This month, their randomized controlled trial found that the therapy incited brain healing and improved myriad symptoms in long Covid sufferers, an area where solutions have been elusive.

But its his recent research on healthy individuals that has such extraordinary implications for the wellness world. The therapy was recently shown to significantly improve (not just slow the loss of) cognitive function in healthy, older adults by generating new neurons and blood vessels in the brainthe first study to demonstrate that a brain can be made younger. Another recent study revealed that the treatment reversed two major processes associated with aging and its illnesses: the shortening of telomeres (the protective caps at the ends of every chromosome) and the accumulation of old, malfunctioning cells in the body. Participants telomeres were lengthened up to 38% while senescent cells saw a decrease of up to 37%.

Our new studies demonstrate something for the first time and its the holy grail of wellness: We can actually reverse the biology of aging and take cellular and brain function back in time. Its analogous to the first time that man landed on the moon. After that first landing, everyone wanted to travel there, but even faster and more effectively. So, well see young scientists rush to study aging and huge investment in this area, said Efrati. Aging isnt a bad thing; its the functional decline that is. As the wellness world knows well, many more people seek solutions that can make them fully potent and active every single year of their life. The future is high-performance aging, and Im excited to share my vision of that futureand the rising place of hyperbaric oxygen therapy in the medical-wellness worldwith the leaders that will gather at the Summit.

Caution: This isnt the hyperbaric oxygen treatment at your corner spa:

Hyperbaric oxygen treatments are spawning at spas and wellness centers and with at-home products. But, as Efrati cautions, its not even the same approach: these offerings simply involve putting people in a sack, or pod, full of minimally pressurized, oxygenated air, when thats not what makes HBOT effective. The game-changing component is the hyperoxic-hypoxic paradox: the precise protocols weve optimized for oxygen and pressure levels, fluctuations, and durations that spark the regenerative process in the body, said Efrati. This evidence-based therapy has to be performed in a medical facility by a trained physician. All these oxygen spas and pods can be dangerous: they miss the quality assurance of the air pump being inside, and they pose threats of oxygen toxicity and other health issues. Theyre also not effective. The future is clearing up much confusion in the marketplace about what evidence-based hyperbaric oxygen therapy actually entails and achieves.

Aviv Clinics: Rolling out this evidence-based treatment globally:

To make a more powerful global impact and to walk faster, Efrati co-founded AVIV Scientific, a research organization and network of global medical-wellness clinics focused on innovative applications of hyperbaric medicine using the HHP protocols, that can increase cognitive and physical performance in healthy aging adults. Clinics are open in Tel Aviv, at The Villages in central Florida, and most recently in Dubaiand are expected to come to New York and the UK soon. Aviv plans 50 clinics around the world within the next decade. Each clinic combines HBOT with personalized medicine, cognitive and fitness training, and nutrition coaching. Thanks to an exclusive partnership with the worlds largest hyperbaric research facility, the Sagol Center at Shamir Medical Center, each patient's data and samples are sent to the centers large research lab, where blood, DNA, telomeres, MRI results, etc. are analyzed. Since Sagol Center is doing so much research, positive findings can immediately be implemented at the clinics. For instance, with their new trial indicating that HBOT can help with long Covid damage to the brain, new programs were quickly rolled out.

Every year we aim to bring the brightest stars in health and wellness to the stage, and Dr. Efrati is exactly the kind of innovator we seek: a dynamic thinker whose work will really shake up our future, whose solutions are grounded in evidence, and who understands that new connections between medicine and wellness lie ahead, said Susie Ellis, GWS chair and CEO. Its an incredible opportunity for delegates to be immersed in his research on the future of aging at such an early, pivotal moment. What hes doing is game-changing.

Registration for the 2022 Summit is now open.

About the Global Wellness Summit The Global Wellness Summit is the premier organization that brings together leaders and visionaries to positively shape the future of the $4.4 trillion global wellness economy. Its future-focused conference is held at a different global location each year and has traveled to the United States, Switzerland, Turkey, Bali, India, Morocco, Mexico, Austria, Italy and Singapore. GWS also hosts other virtual and in-person gatherings, including Wellness Master Classes, Wellness Sector Spotlights, Investor Reverse Pitch events and Global Wellness Symposiums. The organizations annual Global Wellness Trends Report offers expert-based predictions on the future of wellness. The 2022 Summit will be held in Tel Aviv, Israel from October 31 to November 3.

Share article on social media or email:

Continue reading here:
Shai Efrati, MD, the World's Leading Research Scientist and Innovator in Hyperbaric Medicine, to Keynote at the Global Wellness Summit - PR Web

When Herminia Pasantes Ordez was about 14 years old, in 1950, she heard her mother tell her father that she would never find a husband. Pasantes had to wear thick glasses for her poor eyesight. In her mothers eyes, those glasses meant her future as a good woman was doomed. This made my life easier, says Pasantes, because it was already said that I was going to study.

At a time when it was uncommon for women to become scientists, Pasantes studied biology at the National Autonomous University of Mexico in Mexico City, or UNAM. She was the first member of her family to go to college.

Headlines and summaries of the latest Science News articles, delivered to your inbox

Thank you for signing up!

There was a problem signing you up.

She became a neurobiologist and one of the most important Mexican scientists of her time. Her studies on the role of the chemical taurine in the brain offer deep insights into how cells maintain their size essential to proper functioning. In 2001, she became the first woman to earn Mexicos National Prize for Sciences and Arts in the area of physical, mathematical and natural sciences.

We basically learned about cell volume regulation through the eyes and work of Herminia, says Alexander Mongin, a Belarusian neuroscientist at Albany Medical College in New York.

Pasantes did get married, in 1965 while doing her masters in biochemistry at UNAM. She had a daughter in 1966 and a son in 1967 before starting a Ph.D. in natural sciences in 1970 at the Center for Neurochemistry at the University of Strasbourg in France. There, she worked in the laboratory of Paul Mandel, a Polish pioneer in neurochemistry.

The lab was trying to find out everything there was to know about the retina, the layer of tissue at the back of the eye that is sensitive to light. Pasantes decided to test whether free amino acids, a group that arent incorporated into proteins, were present in the retinas and brain of mice. Her first chromatography a lab technique that lets scientists separate and identify the components of a sample showed an immense amount of taurine in both tissues. Taurine would drive the rest of her scientific career, including work in her own lab, which she started around 1975 at the Institute of Cellular Physiology at UNAM.

Taurine turns out to be widely distributed in animal tissues and has diverse biological functions, some of which were discovered by Pasantes. Her research found that taurine helps maintain cell volume in nerve cells, and that it protects brain, muscle, heart and retinal cells by preventing the death of stem cells, which give rise to all specialized cells in the body.

Contrary to what most scientists had believed at the time, taurine didnt work as a neurotransmitter sending messages between nerve cells. Pasantes demonstrated for the first time that it worked as an osmolyte in the brain. Osmolytes help maintain the size and integrity of cells by opening up channels in their membranes to get water in or out.

Pasantes says she spent many years looking for an answer for why there is so much taurine in the brain. When you ask nature a question, 80 to 90 percent of the time, it responds no, she says. But when it answers yes, its wonderful.

Pasantes lab was one of the big four labs that did groundbreaking work on cell volume regulation in the brain, says Mongin.

Her work and that of others proved taurine has a protective effect; its the reason the chemical is today sprinkled in the containers that carry organs for transplants. Pasantes work was the foundation for our understanding of how to prevent and treat brain edema, a condition where the brain swells due to excessive accumulation of fluid, from head trauma or reduced blood supply, for example. She and other experts also reviewed the role of taurine for Red Bull, which added the chemical to its formula because of potentially protective effects in the heart.

Pasantes stopped doing research in 2019 and spends her time talking and writing about science. She hopes her story speaks to women around the world who wish to be scientists: It is important to send the message that it is possible, she says.

Years before she was accepted into Mandels lab, her application to a Ph.D. in biochemistry at the UNAM was rejected. Pasantes says the reason was that she had just had her daughter. Looking back, this moment was one of the most wonderful things that couldve happened to me, Pasantes says, because she ended up in Strasbourg, where her potential as a researcher bloomed.

Rosa Mara Gonzlez Victoria, a social scientist at the Autonomous University of the State of Hidalgo in Pachuca, Mexico, who specializes in gender studies, recently interviewed Pasantes for a book about Mexican women in science. Gonzlez Victoria thinks Pasantes response to that early rejection speaks to the kind of person she is: A woman that takes those nos and turns them into yess.

See more here:
Herminia Pasantes revealed one of taurines big roles in the brain - Science News Magazine

A JOURNALIST revealed the chilling clue that disclosed her lover and famed surgeon as a "romance scammer."

Documentary producer Benita Alexander thought it was love when her job introduced her to internationally renowned surgeon Paolo Macchiarini.

5

5

5

5

Benita was pursuing a big story when the ill-fated lovers met in 2013.

A successful TV journalist, the single mother-of-one was interviewing him for a report on cutting-edge medicine.

"I was doing a story about regenerative medicine and his name kept coming up," Benita, a New York resident, said on the podcast Dr Death: Miracle Man.

Macchiarini had been credited with developing innovative surgical techniques using stem cells in synthetic trachea transplants.

They became friends and over time she felt herself falling for him, despite her journalistic integrity impeding the romance.

"He seemed like he was the miracle man," she said.

"He was a top doctor, he spoke six or seven languages.

"He was a good listener and gave me sage and solid advice."

In mid-2013, they became a couple and in December that year they became pre-engaged as Macchiarini, who lived in Barcelona, Spain, said he was still legally married with two children but had been separated for a long time and was filing for divorce.

It was eight months later when they became properly engaged after Macchiarini presented her with a $100K ring.

The couple had the wedding planned for July 2015.

"The headline is that it started out as a beautiful love story and it ended up as a total nightmare," said Benita.

"I, to this day, have no idea why he lied about our entire relationship."

Macchiarini and Benita quickly started planning an extravagant wedding, she said.

It was beyond Benita's wildest dreams - Macchiarini reportedly told her he invited Bill Clinton, Barack Obama, and Elton John, and that the Pope himself would oversee the ceremony.

It was at this point that Benita said she started to feel that something was not right.

After doing some digging, it transpired that Macchiarini was not the medical genius she thought he was.

In fact, the scientist was embroiled in lawsuits and accusations at work.

"I went full on into investigator mode as I knew he wouldnt tell me the truth," Benita said.

She found out exactly what hed lied about - and she said it was extensive.

He had told her, as personal surgeon to the Pope, the leader of the Catholic church wanted to marry the couple, she explained.

"He said he was having trouble finding a priest to marry us," she said.

"Then he said he had connections to the Vatican. It wasnt surprising being a surgeon in Italy.

"He [the Pope] wanted to use us as the poster couple for the Catholic church, to prove people who are divorced can get married in the Catholic church."

But Benita's intuition overtook her and she hired a private investigator to look into the surreal wedding.

"None of these people were coming," Benita said she tragically discovered.

"He didnt know Pope Francis, he wasnt his personal doctor."

The slip from "Prince Charming to pathological liar" took place over just two years, she said.

In July 2015 their "cat and mouse game" came to an end when she revealed to him everything she found through the private investigation.

"I put it all in a message. He responded wow,'" Benita claimed.

Macchiarini ran into some legal trouble regarding his stem cell treatments with Swedish prosecutors recently appealing a sentence given to the Italian surgeon, the Associated Press reported.

He was put on trial after his patients reportedly suffered bodily harm during his experimental surgeries but he always denied any criminal wrongdoing.

ABC News reported that Macchiarini has never spoken publicly about his relationship with Benita.

Benita and Macchiarini's wild relationship was featured in a special episode of ABC's 20/20 on Friday.

5

Here is the original post:
Journalist Benita Alexander reveals chilling clue that told her Miracle Man Paolo Macchiarini was a rom... - The US Sun

Researchers in London found that male skin cancer deaths increased by 219% since 1973, compared to 76% for women in the same period. Meanwhile, a separate study found that Black and Latino cancer patients experienced more delays in care than white patients. Other research covers covid, menstruation, Alzheimer's, and more.

Fox News:Men's Skin Cancer Deaths Are Higher Than Women's: New AnalysisCancer Research UK an independent cancer research organization in London examined skin cancer fatality records.The group found that male melanoma skin cancer deaths have increased by 219% since 1973.(Moore, 7/17)

CIDRAP:Cancer Treatment Delays Spotlighted In Minority Groups Amid COVID-19A higher proportion of Black (75.6%) and Latino (80.2%) participants and those of other races (75.9%) experienced care modifications, including delayed clinic visits, lab tests, and imaging, as well as a change in care location than White participants (57.1%). A higher proportion of Black (98.0%) than White respondents (84.1%) who had care modifications said their clinic or physician requested the modifications. (7/15)

On covid research news

The New York Times:Covid-19 Vaccines Temporarily Changed Menstrual Cycles, Study ShowsNearly half of the participants of a recent study who were menstruating regularly at the time of the survey reported heavier bleeding during their periods after receiving the Covid-19 vaccine. Others who did not typically menstruate including transgender men, people on long-acting contraceptives, and post-menopausal women also experienced unusual bleeding. (Sheikh, 7/15)

CBS News:Studying The Effects Of Long COVIDSince contracting COVID-19 back in January 2021, Ken Todd has never made a full recovery, making him one of the millions who suffer from "long COVID." (7/17)

CIDRAP:More (Mostly Mild) Side Effects When Flu Vaccine Given With COVID BoosterSelf-reported data from nearly 1 million Americans show an 8% to 11% higher rate of mostly mild systemic adverse events after simultaneous seasonal flu vaccine and mRNA COVID-19 booster (third) doses than with the COVID-19 booster alone. (Van Beusekom, 7/15)

In news about other research

CIDRAP:Study Shows Global Rise In Macrolide-Resistant Mycoplasma PneumoniaeAntibiotic resistance, one of the most common causes of community-acquired pneumonia (CAP) in children, has risen dramatically over the past two decades, according to a study published this week in JAMA Network Open. To analyze global patterns, temporal trends, and regional variations in macrolide-resistant Mycoplasma pneumoniae (MRMP) infections, a team of South Korean researchers conducted a systematic review and meta-analysis of 153 studies from 150 articles published prior to Sep 10, 2021. (7/15)

Zenger News:Glass Of Wine A Day May Lead To Alzheimer's, Research SuggestsJust one small glass of wine a day could give you Alzheimer's or Parkinson's, according to new research. Consuming just seven units of alcohol a week - half the recommended maximum - fuels iron in the brain. (Kitanovska, 7/16)

AP:High-Flying Experiment: Do Stem Cells Grow Better In Space?Researcher Dhruv Sareens own stem cells are now orbiting the Earth. The mission? To test whether theyll grow better in zero gravity. Scientists at Cedars-Sinai Medical Center in Los Angeles are trying to find new ways to produce huge batches of a type of stem cell that can generate nearly any other type of cell in the body and potentially be used to make treatments for many diseases. The cells arrived over the weekend at the International Space Station on a supply ship. (Ungar, 7/17)

Also, in innovations

The Wall Street Journal:High-Tech Smell Sensors Aim To Sniff Out Disease, ExplosivesAnd Even MoodsBut now scientists and entrepreneurs are redoubling their efforts to recreate the sense of smell in compact devices that detect and analyze odors similar to the way cameras now recognize our faces and microphones our words. In pursuit of these high-tech deviceswhich could use odors to detect disease like cancer or Covid-19, locate hidden explosives or decipher our moods and behaviorssome companies are leveraging advances in synthetic biology and genetic engineering. Others are harnessing advances in artificial intelligence. (Hernandez, 7/16)

Reuters:Roche Launches Dual Antigen And Antibody Diagnostic Test For Hepatitis CRoche (ROG.S) has launched an new dual antigen and antibody diagnostic test for hepatitis C, the Swiss pharmaceuticals company said on Monday, which it says will give an earlier diagnosis of the virus. The Elecsys HCV Duo is the first commercially available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus status from a single human plasma or serum sample. (7/18)

Read more:
Melanoma Kills Nearly Twice The Number Of Men Than Women: Study - Kaiser Health News

Desperate to have their lives back, long COVID patients are turning to an expensive last resort therapy to cure the mysterious illness.

Apheresis, or blood washing, is a process in which a component of blood, such as plasma, is separated and then filtered back into your body via giant needles inserted into a vein.

Gitte Boumeester, who found out about blood washing through a Facebook support group, spent more than $15,000 to have the treatment, BMJ and ITV News reported, in a joint investigation out Tuesday.

I thought, whats the worst thing Ive got to lose? the Dutch psychiatrist-in-training told reporters. Money was the only thing.

And that she did once Boumeester concluded, two months after the procedure, that the blood washing didnt work.

The process is typically used in cases where its necessary to remove specific components of blood, such as the treatment of blood cancers, plasma and platelet donation or to collect stem cells.

But in Germany, doctors consider it one of the last resorts for the treatment of some lipid disorders, which are marked by abnormal levels of lipids, or fats, in the blood the effects of which some have theorized are similar to long-term COVID infection.

Boumeesters battery of tests revealed nothing about her condition, which developed soon after she caught the SARS-CoV-2 virus in November 2020, despite her debilitating exhaustion.

Yet some researchers, namely Dr. Beate Jaeger, have hypothesized that long COVID may be caused by small clots in the blood that get in the way of the flow of oxygen, leading to the telltale extreme fatigue and muscle aches. Thus, washing the blood of unnecessary lipids and proteins, in combination with the use of anticoagulants, blood thinners such as clopidogrel, apixaban and heparin, could help clear the capillaries for better blood circulation.

Jaeger, a cardiovascular specialist in Mlheim, Germany, fought to see apheresis used on COVID patients in the ICU and to publish a paper on her approach, attempts of which were denied. Finally, a pair of her patients agreed to undergo the treatment free of charge. Then, 60 more opted-in. Shes since seen extremely successful results in thousands of patients, she said.

In one of her reports, Jaeger claimed that a long COVID patient who used a wheelchair could miraculously walk again following treatment. Another improved their stride from a labored walk to a jog.

Beverley Hunt, medical director of the charity Thrombosis UK, told BMJ, I am worried these patients have been offered therapies which have not been assessed by modern scientific methods: well-designed clinical trials. In this situation the treatment may or may not benefit them but, worryingly, also has the risk of harm.

The process of apheresis is safe if properly performed, but there are potentially dire consequences to having overly-thin blood, particularly if hemorrhage occurs.

Even under the safest conditions, patients also risk financial ruin. Boumeester traveled some 1,700 air miles to the Long Covid Center in Larnaca, Cyprus. For two months, she rented an apartment on the beach while making weekly appointments for apheresis, and more unproven add-on therapies, such as hyperbaric oxygen and intravenous vitamin infusions.

Six rounds of blood washing cost her more than $1,600 per session, while additional treatments came with price tags up to about $150, which she did on the recommendation of the clinicians.

I was a little ambivalent about all the extra treatment, but I promised myself if I was there I would do anything, to just try, she said.

Experimental treatments are generally permitted throughout Europe as long as theres clear patient consent, but experts fear that clinics like the Long Covid Center may be overpromising.

People could potentially go bankrupt accessing these treatments, for which there is limited to no evidence of effectiveness, said University of Birmingham researcher Shamil Haroon, whose work on the Therapies for Long Covid in Non-hospitalized Patients trial will eventually go on to inform how doctors approach the disease.

Like Boumeester, British businessman Chris Witham, from Bournemouth, traveled across the continent, toKempten, Germany, for a $7,000 course of apheresis that didnt work.

Id have sold my house and given it away to get better, without a second thought, he told BMJ and ITV News.

The outlets spoke to just six long COVID patients who said the procedure improved some of their condition, though symptoms lingered.

Their reporting flies in the face of claims made by Austrian entrepreneur and long COVID sufferer Markus Klotz, who founded the clinic in Cyprus and claims it worked for him after having the treatment with Jaegar in Mlheim. Over 80% of patients report to keep their gains permanently, read one post on the Facebook page for the Apheresis Association, also led by Klotz.

I realized before I started that the outcome was uncertain, but everyone at the clinic is so positive that you start to believe it too and get your hopes up, Boumeester said.

Read more here:
Patients have turned to pricey 'blood washing' to treat long COVID - New York Post

HEIDELBERG, Germany, June 10, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. ( AFMD) (Affimed or the Company), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today presented a poster at the Annual Meeting of the European Hematology Association (EHA) in Vienna, Austria. The data demonstrate the cytotoxic potential of the CD123/CD16A-targeting bispecific innate cell engager (ICE) AFM28 which is in development as a novel treatment for patients with myeloid diseases, e. g. relapsed/refractory (R/R) acute myeloid leukemia (AML). AFM28 binds to natural killer (NK) cells and CD123-positive tumor cells and demonstrated the induction of tumor cell killing in vitro and a good tolerability and strong anti-tumor activity in vivo.

It is widely acknowledged that targeting CD123 holds significant untapped promise in developing better AML therapies. We believe our differentiated approach in targeting CD123 has the potential to provide a novel, innate immune system-engaging therapy to improve clinical outcomes, said Dr. Arndt Schottelius, Chief Scientific Officer at Affimed. Following these encouraging pre-clinical proof-of-concept data and the experience we have gained from our AFM13 studies so far, we will be launching a first-in-human clinical study to investigate the compounds safety, efficacy and biological activity as monotherapy later this year and in combination with adoptive NK cells soon after.

The data presented at EHA today provide validation of the mechanism of action (MoA) as well as preclinical proof-of-concept for AFM28 in a range of in vitro and in vivo assays. AFM28 exhibited high-affinity binding to CD16A expressed on NK cells and high avidity conferring long cell surface retention in comparison to Fc-enhanced anti-CD123 antibody. Moreover, AFM28 demonstrated the ability to destroy CD123-positive tumor cell lines and primary leukemic cells via antibody-dependent cell-mediated cytotoxicity (ADCC).

Importantly, AFM28 was active irrespective of mutational status of tumor cells and also induced depletion when CD123 expression was very low. Strikingly, AFM28 was also active against cells not killed by an Fc-enhanced CD123-targeting comparator antibody suggesting the potential for improved clinical effectiveness. Moreover, AFM28 also depleted leukemic cells from patient bone marrow without destroying CD34-positive/CD123-negative cells, suggesting sparing of hematopoietic stem and progenitor cells.

In vivo studies in an AML murine model demonstrated anti-tumor efficacy, and cynomolgus toxicology models predicted pharmacodynamic activity with a well-tolerated safety profile and low risk of cytokine release syndrome.

Efficient depletion of leukemic blasts and leukemic stem cells is critical for inducing long-term remission in AML patients. As both cell types express CD123, AFM28s ability to redirect NK cells to this target killing both leukemic blasts and leukemic stem cells makes this an attractive treatment strategy. Currently, there are no curative immunotherapies available, the only option is allogenic hematopoietic stem cell transplantation (allo-HSCT).

Affimed plans to initiate clinical development of AFM28 with a first-in-human phase 1 monotherapy trial in adult patients with R/R AML in the second half of 2022. In addition, Affimed plans to investigate AFM28 in combination with allogeneic NK cell therapy after a safe starting dose has been determined.

The full poster is accessible through the following link: Publications and Posters - Affimed

Poster details:

Title: Novel bispecific innate cell engager AFM28 for the treatment of CD123-positive acute myeloid leukemia and myelodysplastic syndrome

Authors: Jana-Julia Siegler, Nanni Schmitt, Jens Pahl, Torsten Haneke, Izabela Kozlowska, Sverine Sarlang, Alexandra Beck, Stefan Knackmuss, Paulien Ravenstijn, Uwe Reusch, Jos Medina-Echeverz, Jan Endell, Thorsten Ross, Daniel Nowak, and Christian Merz

Final abstract code: P482

Session date and time: Poster session on Friday, June 10th, 10:30 11:45 a.m. EDT / 16:30 - 17:45 CEST

About AFM28

AFM28, a tetravalent, bispecific CD123- and CD16A-binding ICE developed on Affimeds ROCK platform, is designed to bring a new immunotherapeutic treatment to patients with CD123+ myeloid malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). It engages NK cells to initiate tumor cell killing via antibody-dependent cellular cytotoxicity (ADCC), even at low CD123 expression levels. Clinical development is planned as both monotherapy and in combination with allogeneic NK cells in patients with relapsed/refractory CD123-positive leukemias.

About Affimed N.V.

Affimed ( AFMD) is a clinical-stage immuno-oncology company committed to give patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Companys proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager (ICE) molecules, which use patients immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE. Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients lives. For more about the Companys people, pipeline and partners, please visit: http://www.affimed.com.

Investor Relations Contact

Alexander FudukidisDirector, Investor RelationsE-Mail: [emailprotected]Tel.: +1 (917) 436-8102

Media Contact

Mary Beth Sandin Vice President, Marketing and CommunicationsE-Mail: [emailprotected] Tel.: +1 (484) 888-8195

Read the original here:
Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA) -...

[250 Pages Report]As per a latest industry analysis by Future Market Insights, the global interferons market was valued at around US$ 9.1 Bn in 2021 and is anticipated to exhibit a CAGR of 3.9% over the forecast period (2022-2032).

A group of proteins produced by white blood cells, fibroblasts, and T-cells in response to viral infections, bacteria, tumor cells, and other pathogens are known as interferons. These glycoproteins, also known as cytokines, are frequently referred to as the first line of defense against pathogens.

Request Sample Copy of [emailprotected]https://www.futuremarketinsights.com/reports/sample/rep-gb-15158

Interferons have proved to be a cutting-edge and successful treatment option for illnesses such as cancer, hepatitis, and multiple sclerosis. In November 2021, for instance, the FDA approved BESREMi for the treatment of adults living with polycythemia vera, which is a recent advancement in the interferons industry.

Polycythemia vera is a group of rare, chronic, and life-threatening blood cancers caused by a mutation in bone marrow stem cells, which further leads to an abundance of blood cells. When this happens, a person is at high risk of significant health problems such as blood clots, strokes, and heart attacks.

One of the other factors driving the global interferons market is rising focus of key players on the development of innovative interferon-beta medications. Key players are also focusing on expanding their presence with the help of promotions, improved distribution networks, and enhanced customer services related to their products for the betterment of the brand and products.

For instance, in March 2020, Bayer and Curadev signed a research collaboration and license agreement to develop a novel stimulator of interferon genes (STING) antagonists across indications. It is known to help activate the innate immune system in auto-inflammatory diseases. Such breakthroughs in the global market are projected to bode well for the interferons industry in the upcoming decade.

Key Takeaways: Interferons Market

Ask from Market Research [emailprotected] https://www.futuremarketinsights.com/ask-question/rep-gb-15158

Growing number of therapeutic interferon approvals and their surging commercial applications in several disease indications are expected to propel the global interferons market, says an analyst of Future Market Insights.

Competitive Landscape: Interferons Market

Leading manufacturers such as Pfizer, Merck & Co., Zydus Cadila, and Novartis AG are focusing on collaborations and acquisitions to enhance their presence in the market and compete with their rivals during the forecast period. Below are some of the latest industry developments by key market participants:

More Valuable Insights on Interferons Market:

Future Market Insights brings a comprehensive research report on projected revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2032. The global interferons market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on the interferons market segments based on product (interferon gamma, interferon beta, and interferon alpha), indication (multiple sclerosis, polycythemia vera, hepatitis C, melanoma, chronic granulomatous disease (CGD), and other indications), and end user (hospital pharmacies, retail pharmacies, specialty clinics, and online pharmacies) across seven major regions.

For in-depth insights, Download a PDF [emailprotected] https://www.futuremarketinsights.com/reports/brochure/rep-gb-15158

Interferons Market Outlook by Category

By Product:

By Indication:

By End User:

Explore Other Reports Links From Healthcare Market

https://www.fmiblog.com/2022/07/06/3d-bio-printing-market-to-grow-at-12-9-cagr-through-2030-report-by-fmi-2/

https://www.fmiblog.com/2022/07/06/intraosseous-infusion-devices-market-key-players-pyng-medical-corp-aero-healthcare-cook-medical-incorporated-persys-medical-2/

https://www.fmiblog.com/2022/07/06/ophthalmic-lasers-market-is-estimated-to-increase-from-a-valuation-of-us-884-3-million-in-2022-7/

https://www.fmiblog.com/2022/07/06/proteinase-k-market-is-projected-to-reach-us-33-4-million-by-the-end-of-2026-5/

https://www.fmiblog.com/2022/07/06/organoids-market-key-players-cellesce-ltd-definigen-qgel-hubrecht-organoid-technology-hub-ocello-b-v-2/

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:Future Market Insights,Unit No: 1602-006,Jumeirah Bay 2,Plot No: JLT-PH2-X2A,Jumeirah Lakes Towers,Dubai,United Arab EmiratesFor Sales Enquiries:[emailprotected]uturemarketinsights.comWebsite:https://www.futuremarketinsights.comLinkedIn|Twitter|Blogs

The post Interferons Market is anticipated to reach US$ 13.8 Bn by 2032, at a CAGR of 3.9% from 2022 to 2032 appeared first on Future Market Insights.

Read the original post:
Interferons Market is anticipated to reach US$ 13.8 Bn by 2032, at a CAGR of 3.9% from 2022 to 2032 - Digital Journal